Syncona Limited Autolus announces partial exercise of ADS option (5430K)
22 Diciembre 2022 - 1:00AM
UK Regulatory
TIDMSYNC
RNS Number : 5430K
Syncona Limited
22 December 2022
Syncona Limited
Autolus Announces Partial Exercise of Underwriters' Option to
Purchase Additional ADSs
22 December 2022
Syncona Ltd, a leading healthcare company focused on creating,
building and scaling global leaders in life science, notes that its
portfolio company, Autolus Therapeutics plc ("Autolus") yesterday
announced that the underwriters of its previously announced public
offering of American Depositary Shares ("ADSs") which closed on
December 13, 2022, have partially exercised their option to
purchase an additional 6,927,102 ADSs, at a price per ADS of $2.00,
resulting in additional gross proceeds to Autolus of approximately
$13.9 million (GBP11.5 million) [1] . After giving effect to the
issuance of these additional shares, which closed yesterday,
Autolus has sold a total of 81,927,102 ADSs in the offering for
aggregate gross proceeds of approximately $163.9 million (GBP135.6
million).
Syncona invested approximately $28.0 million (GBP23.2 million)
in the offering. Following the offering, Syncona retains a stake of
approximately 17.9% in Autolus (amounting to 33,527,163 ordinary
shares) which was valued at GBP55.5 million on 21 December 2022
according to the offering price.
This announcement does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
The securities described above were offered by Autolus pursuant
to an effective shelf registration statement that was previously
filed with the U.S. Securities and Exchange Commission ("SEC"). A
final prospectus supplement to the accompanying prospectus
describing the terms of the offering was filed with the SEC. The
offering was made only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement, which, for the avoidance of doubt, does not constitute a
"prospectus" for the purposes of the Regulation (EU) 2017/1129 and
has not been reviewed by any competent authority in any member
state in the European Economic Area. Copies of the final prospectus
supplement and the accompanying prospectus relating to the offering
may be obtained for free from either of the joint book-running
managers for the offering, Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by telephone at +1 877 821 7388 or by email at
Prospectus_Department@Jefferies.com; William Blair & Company,
L.L.C., Attention: Prospectus Department, 150 North Riverside
Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by
email at prospectus@williamblair.com; or Wells Fargo Securities,
LLC, Attention: Equity Syndicate Department, 500 West 33rd Street,
New York, New York, 10001, at (800) 326-5897 or email a request to
cmclientsupport@wellsfargo.com .
[ENDS]
Enquiries
Syncona Ltd
Annabel Clark / Fergus Witt
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Julia Bradshaw / Tim
Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life.
We do this by creating and building companies to deliver
transformational treatments to patients in areas of high unmet
need.
Our strategy is to create, build and scale companies around
exceptional science to create a diversified portfolio of 20-25
globally leading healthcare businesses, across development stage
and therapeutic areas, for the benefit of all our stakeholders. We
focus on developing treatments for patients by working in close
partnership with world-class academic founders and management
teams. Our balance sheet underpins our strategy enabling us to take
a long-term view as we look to improve the lives of patients with
no or poor treatment options, build sustainable life science
companies and deliver strong risk-adjusted returns to
shareholders.
About Autolus
Autolus is a clinical-stage biopharmaceutical company developing
next-generation, programmed T cell therapies for the treatment of
cancer. Using a broad suite of proprietary and modular T cell
programming technologies, Autolus is engineering precisely
targeted, controlled and highly active T cell therapies that are
designed to better recognize cancer cells, break down their defense
mechanisms and eliminate these cells. Autolus has a pipeline of
product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information,
please visit www.autolus.com.
[1] All exchange rates taken at 21 December 2022
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUFEIEFFEESEEE
(END) Dow Jones Newswires
December 22, 2022 02:00 ET (07:00 GMT)
Syncona (LSE:SYNC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Syncona (LSE:SYNC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024